Reliable Data
Are you measuring at the right moment?
THE PROBLEM: WHEN IS THE RIGHT MOMENT TO MEASURE?
An estimated 1.4 billion adults aged 30-79 years worldwide have hypertension, with 44% unaware of their condition (WHO)[1].
Blood Pressure is intended to be measured when a person is in a relaxed physiological state[2]. The World Health Organization (WHO) Guidelines mandate:
- Relax & sit with straight back for at least 5 minutes.
- No talking while relaxing before measurement.
- Repeated measurements and average the readings.
All in a busy home or 10-15 minute GP consultation?
OUR SOLUTION: ASSESS BEFORE YOU MEASURE
By determining the physiological state of a patient, we can drastically optimize the clinical workflow while improving:
Our patent-pending technology (PCT) unlocks huge market potential by assessing physiological state before measurement. Using advanced algorithms and bio-signals (ECG/PPG), our platform identifies the perfect moment to take a reading, delivering a frictionless, world-class user experience.
The Opportunity
Wavescope’s ambition doesn’t stop at blood pressure readiness. It expands into primary healthcare and AI-driven clinical decision support.
Blood Pressure Measurement IP Platform
Pre Clinic Vital Signs Assessment (PCVSA) in Primary Healthcare[5]
Enables Data Business & Decision Support System
Regulatory & Reimbursement
Target Regulatory Pathway
Target pathway prioritizes US FDA premarket clearance followed by European CE Mark Certification (Class IIa MDR).
Target 510(k) Pathway under 21 CFR 870.1130
Class II predicate pathway (Product Code DXN: Noninvasive blood pressure measurement system). Investigational technology currently in development; not cleared for commercial diagnostic marketing.Prospective Reimbursement Alignment
Commercial strategy is architected to integrate into established clinical reimbursement frameworks upon regulatory clearance.
Designed for Established CPT & RPM Frameworks
Designed to support clinical workflows under CPT 99473/99474 (self-measured blood pressure setup and monthly analysis) and CPT 99453–99458 (Remote Patient Monitoring). Aims to support provider clinical quality benchmarks including MIPS Quality 236 (Controlling High Blood Pressure).*Statements describe investigational development targets. Wavescope is not currently cleared by the FDA or CE notified bodies for diagnostic use or commercial billing.
Partners & Consortium
AINM DTIF Consortium & Backers
Supported by €1 million in non-dilutive matched funding from the Irish Government via the Disruptive Technologies Innovation Fund.
Leadership
Our Team
Alan Gormley
Chief Commercial OfficerInnovator, influencer, strategist, expert in global standards and product commercialization.
Sean McMahon
CEO & Co-FounderMedTech engineer and AI researcher pioneering high-precision bio-signal devices, clinical workflow optimization, and neural network diagnostics to deliver reliable, actionable vital signs data.
Dr Jennifer Grant
Chief Medical OfficerQualified Doctor & Pharmacist. Clinical Lead at Beacon Health Check. Over 20 years clinical experience.
James Sheil
Head of Design20 years experience in Digital Product, Human Factors, Usability, and UX Design.
Advisory Board
Our Advisors
Steen Gordon
Commercial AdvisorExpert in strategic growth, partnerships, and commercial development.
Peter Corscadden
Strategic AdvisorExecutive expert in health technology scale-up and enterprise AI solutions.
What's New
Clinical Evidence & News
Today's data is tomorrow's AI
In Wavescope, we believe in accurate, precise, and reliable blood pressure measurements. Our research led us to file an international patent through the PCT system.
Contact
Contact Us
Connect With Us
Our Location
Wavescope Ltd, Workhub
51 Bracken Road, D18CV48, Ireland